Loading clinical trials...
Loading clinical trials...
An Open Short-term Clinical Pilot Trial on Safety and Immunogenicity of Nasal COVID-19 Vaccine at Different Dose Levels and Administration Methods
COV2 is a nasal, investigational vaccine against COVID-19, based on a serotype 5 adenoviral vector producing the SARS-CoV-2 spike protein. In this trial, the primary comparison in terms of safety and immunogenicity will be between two different dose levels of COV2 booster vaccine (low, high), and two different administration methods (nasal drops, nasal spray). In addition, COV2 vaccine will also be evaluated in vaccine naive subjects.
Age
18 - 75 years
Sex
ALL
Healthy Volunteers
Yes
Kuopio University Hospital
Kuopio, Northern Savonia, Finland
Start Date
January 21, 2025
Primary Completion Date
June 25, 2025
Completion Date
June 26, 2025
Last Updated
December 8, 2025
40
ACTUAL participants
COVID-19 vaccine, low dose level
BIOLOGICAL
COVID-19 vaccine, high dose level
BIOLOGICAL
Nasal Drops
OTHER
Nasal Spray
OTHER
Lead Sponsor
Rokote Laboratories Finland Oy
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions